Key Insights on Danaher's Stock Performance

By Harris Dyer • Friday, May 08 16:03 • Permanent Link

One of the losers of today's trading session was Danaher. Shares of the Farm & heavy construction machinery company plunged -2.6%, and some investors may be wondering if its price of $171.13 would make a good entry point. Here's what you should know if you are considering this investment:

Danaher has moved -7.4% over the last year, and the S&P 500 logged a change of 29.6%
DHR has an average analyst rating of buy and is -31.58% away from its mean target price of $250.14 per share
Its trailing earnings per share (EPS) is $5.16
Danaher has a trailing 12 month Price to Earnings (P/E) ratio of 33.2 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $9.09 and its forward P/E ratio is 18.8
The company has a Price to Book (P/B) ratio of 2.29 in contrast to the S&P 500's average ratio of 4.74
Danaher is part of the Industrials sector, which has an average P/E ratio of 24.03 and an average P/B of 2.89
DHR has reported YOY quarterly earnings growth of 9.8% and gross profit margins of 0.6%
The company has a free cash flow of $4.57 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.